Elutia Inc
ELUT
查看详细走势图
1.080USD
+0.010+0.93%
交易中 （美东）报价延迟15分钟
11.04M总市值
0.84市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.93%
5天
-1.82%
1月
-6.09%
6月
+16.13%
今年开始到现在
+55.91%
1年
-59.09%
查看详细走势图
TradingKey Elutia Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Elutia Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名80/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.00。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Elutia Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Elutia Inc亮点
亮点风险
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
业绩增长期
公司处于发展阶段，最新年度总收入12.29M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值0.83，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值102.12K
分析师目标
根据
1
位分析师
买入
评级
5.000
目标均价
+367.29%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Elutia Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Elutia Inc简介
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
公司代码ELUT
公司Elutia Inc
CEOMills (C. Randal)
网址https://elutia.com/
相关品种
